Breast Cancer Subtype Approximations and Loco-regional Recurrence After Immediate Breast Reconstruction
Overview
Oncology
Authors
Affiliations
Background: A small but significant proportion of patients with breast cancer (BC) will develop loco-regional recurrence (LRR) after immediate breast reconstruction (IBR). The LRR also varies according to breast cancer subtypes and clinicopathological features.
Methods: We studied 1742 consecutive BC patients with IBR between 1997 and 2006. According to St Gallen conference consensus 2011, its BC approximations were applied to classify BC into five subtypes: estrogen receptor (ER) and/or progesterone receptor (PgR) positive, HER2 negative, and low Ki67 (<14%) [luminal A]; ER and/or PgR positive, HER2 negative and high Ki67(≥ 14%) [luminal B/HER2 negative]; ER and/or PgR positive, any Ki67 and HER2 positive [luminal B/HER2 positive]; ER negative, PgR negative and HER2 positive [HER2 positive/nonluminal]; and ER negative, PgR negative and HER2 negative [triple negative]. Cumulative incidences of LRR were compared across different subgroups by means of the Gray test. Multivariable Cox regression models were applied.
Results: Median follow up time was 74 months (range 3-165). The cumulative incidence of LRR was 5.5% (121 events). The 5-year cumulative incidence of LRR was 2.5% for luminal A; 5.0% for luminal B/HER2 negative; 9.8% for luminal B/HER2 positive; 3.8% for HER2 non luminal; and 10.9% for triple negative. On multivariable analysis, tumor size (pT) >2 cm, body mass index (BMI) ≥ 25, triple negative and luminal B/HER2 positive subtypes were associated with increased risk of LRR.
Conclusion: Luminal B/HER2 positive, triple negative subtypes and BMI ≥ 25 are independent prognostic factors for risk of LRR after IBR.
Nolan L, Davey M, Calpin G, Ryan E, Boland M Ir J Med Sci. 2024; 193(6):2965-2974.
PMID: 39331262 DOI: 10.1007/s11845-024-03809-z.
Sayyed A, Towfighi P, Deldar R, Aminpour N, Sogunro O, Maini M Transl Breast Cancer Res. 2024; 4:5.
PMID: 38751478 PMC: 11093065. DOI: 10.21037/tbcr-22-42.
Zhao Y, Yan L, Li S, Yang Z, Chai N, Qiu P Cancer Med. 2023; 12(20):20287-20298.
PMID: 37795774 PMC: 10652306. DOI: 10.1002/cam4.6579.
Chan D, Vieira R, Abar L, Aune D, Balducci K, Cariolou M Int J Cancer. 2022; 152(4):572-599.
PMID: 36279884 PMC: 10092239. DOI: 10.1002/ijc.34322.
Triple negative breast cancer: approved treatment options and their mechanisms of action.
Mandapati A, Lukong K J Cancer Res Clin Oncol. 2022; 149(7):3701-3719.
PMID: 35976445 PMC: 10314854. DOI: 10.1007/s00432-022-04189-6.